Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyTumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDYGrowth hormone tumor histological subtypes predict response to surgical and medical therapy.Medical therapy of acromegalySwitching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumorsLong-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.Pharmacokinetic evaluation of lanreotide.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsManagement options for persistent postoperative acromegaly.Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.Pharmacological treatment of acromegaly: its place in the overall therapeutic approach.Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide autogel in acromegaly - a decade on.A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.Adverse events associated with somatostatin analogs in acromegaly.Somatostatin receptor ligands in the treatment of acromegaly.Management of hormone-secreting pituitary adenomas.Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response.Cabergoline treatment in acromegaly: cons.Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.Octreotide LAR treatment of acromegaly in "real life": long-term outcome at a tertiary care center.Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1.Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.
P2860
Q26777682-92DED45D-F2BD-4DD7-AF88-029615F9DBA0Q33564399-FAAD7A7D-D661-4E68-A2DF-CCA82DDEB503Q33569037-B2081FC5-F92B-445F-8DF0-1BAE77918591Q33772673-2983CECB-0678-473C-900B-BC9DDB727424Q33858344-A2824CF0-55D9-4604-A948-7DDF0516608CQ34446297-06D3803B-7742-4991-AE61-9D10267F54F8Q35091578-59E352B3-90C7-421A-BA0E-7FE876C98521Q35895856-DDCFBD96-6665-404F-8B80-46464C6FAF66Q35977997-27BE6D0F-5A1A-4FA6-A288-9C025FAD7928Q35981653-F9DCC989-617C-4E35-884A-43B80A9ABD6FQ36270932-867318D7-24FC-4C7D-AEB0-A0C03917C6FDQ37617510-50739CE1-6235-4837-BC4D-3C1B1E8B0959Q37663006-9F0D64C6-AA17-49D5-B1A5-9A808289FB27Q37780553-BB60B43F-4635-48A5-9D70-9BB3618FBF35Q37980741-E3CE5671-0F52-46EE-A7BD-9794B0E48ABEQ38049832-A70CA781-BB32-491D-AE12-560020FF4AE6Q38062852-7E6A1E13-0447-41F7-AC89-0E5A5B1F1A81Q38179982-C2393777-DE4A-41F7-9E69-AB6A9E5964F6Q38185306-BDA64973-9399-4057-A93E-6D1695528A0DQ38246440-91127F9C-CFCA-4281-8DCF-4E0630F89BD5Q38259409-53C0CB35-7E4A-4832-9AB0-B7D39C92C3C2Q38373377-DD221D69-BD76-444F-98EA-5024EF18DA90Q38548973-B1A57493-8028-433C-B096-5B371A66B2F1Q39125449-919D5F30-E206-4A9F-AA89-1D8119CB0303Q39168432-D18EF5D1-52AC-482A-AA23-AFF869635EF8Q39294965-68FDE5BE-32DA-4F99-B290-16D1780908BFQ45844957-A4AAE25C-02B9-4896-931D-B4F9F691B78FQ47130943-20C4B5FC-47E9-4425-A430-526D535D2841Q48021997-27E4EDC0-F154-4ECA-9CB3-EE1B47281370Q51091069-538EF3E3-83EC-4EB6-81CA-7557AFF61AF1Q51571230-EF9F4022-B6FD-4AD7-8C86-ABBCA091DFE8Q54542028-791EB325-AF0C-41A9-AA77-751D9EF4FA3B
P2860
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Rapid and sustained reduction ...... with a 52 week open extension
@ast
Rapid and sustained reduction ...... with a 52 week open extension
@en
type
label
Rapid and sustained reduction ...... with a 52 week open extension
@ast
Rapid and sustained reduction ...... with a 52 week open extension
@en
prefLabel
Rapid and sustained reduction ...... with a 52 week open extension
@ast
Rapid and sustained reduction ...... with a 52 week open extension
@en
P2093
P2860
P921
P1433
P1476
Rapid and sustained reduction ...... with a 52 week open extension
@en
P2093
David Cook
Jochen Schopohl
Karen S L Lam
Miklos I Goth
Shlomo Melmed
P2860
P2888
P356
10.1007/S11102-009-0191-1
P577
2009-07-29T00:00:00Z